These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

784 related articles for article (PubMed ID: 34689859)

  • 1. Effectiveness of bortezomib and temozolomide for eradication of recurrent human glioblastoma cells, resistant to radiation.
    Pak O; Zaitsev S; Shevchenko V; Sharma A; Sharma HS; Bryukhovetskiy I
    Prog Brain Res; 2021; 266():195-209. PubMed ID: 34689859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study.
    Rahman MA; Brekke J; Arnesen V; Hannisdal MH; Navarro AG; Waha A; Herfindal L; Rygh CB; Bratland E; Brandal P; Haasz J; Oltedal L; Miletic H; Lundervold A; Lie SA; Goplen D; Chekenya M
    Immun Inflamm Dis; 2020 Sep; 8(3):342-359. PubMed ID: 32578964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoplasmic Shotgun Proteomic Points to Key Proteins and Pathways in Temozolomide-Resistant Glioblastoma Multiforme.
    Teraiya M; Krokhin O; Chen VC; Perreault H
    J Proteome Res; 2024 Jan; 23(1):465-482. PubMed ID: 38147655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
    Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
    Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
    Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
    Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells.
    Hellmold D; Kubelt C; Daunke T; Beckinger S; Janssen O; Hauck M; Schütt F; Adelung R; Lucius R; Haag J; Sebens S; Synowitz M; Held-Feindt J
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microarray expression profiles and bioinformatics analysis of mRNAs, lncRNAs, and circRNAs in the secondary temozolomide-resistant glioblastoma.
    Zhao C; Gao Y; Guo R; Li H; Yang B
    Invest New Drugs; 2020 Oct; 38(5):1227-1235. PubMed ID: 31823158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased APE-1 by Nitroxoline Enhances Therapeutic Effect in a Temozolomide-resistant Glioblastoma: Correlation with Diffusion Weighted Imaging.
    Cho HR; Kumari N; Thakur N; Vu HT; Kim H; Choi SH
    Sci Rep; 2019 Nov; 9(1):16613. PubMed ID: 31719653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.
    Yamamuro S; Takahashi M; Satomi K; Sasaki N; Kobayashi T; Uchida E; Kawauchi D; Nakano T; Fujii T; Narita Y; Kondo A; Wada K; Yoshino A; Ichimura K; Tomiyama A
    Cancer Sci; 2021 Nov; 112(11):4736-4747. PubMed ID: 34536314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.
    Yang B; Ma YB; Chu SH
    Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1.
    Wang S; Chen C; Li J; Xu X; Chen W; Li F
    J Neurol Sci; 2020 Jul; 414():116837. PubMed ID: 32334273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
    Liang H; Chen Z; Sun L
    Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51.
    Zhang N; Wu X; Yang L; Xiao F; Zhang H; Zhou A; Huang Z; Huang S
    Clin Cancer Res; 2012 Nov; 18(21):5961-71. PubMed ID: 22977194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.